(IN BRIEF) Sanofi has secured European Commission approval for Sarclisa® subcutaneous administration in combination with standard-of-care regimens for multiple myeloma, covering all indications already approved for the intravenous version of the therapy in the EU. The approval makes Sarclisa the … Read the full press release
Posted in Business, European Union, France, Healthcare, Marketing, Pharma & Biotech, Science, Technology
Tagged anti-CD38 monoclonal antibody, anticancer therapy, biologic therapies, bortezomib, cancer care, carfilzomib, CirCLIQ OBI, Committee for Medicinal Products for Human Use, dexamethasone, Enable Injections, enFuse platform, European Commission, European Commission Approves Sanofi’s Sarclisa Subcutaneous Across Existing EU Multiple Myeloma Indications, European Medicines Agency, European Union, Healthcare Innovation, home administration, IRAKLIA phase 3 study, isatuximab, IZALCO phase 2 study, lenalidomide, MM, Mohamad Mohty, Multiple Myeloma, NCT05405166, NCT05704049, newly diagnosed multiple myeloma, Olivier Nataf, on-body injector, oncology, outpatient treatment, patient-centered care, pomalidomide, relapsed and refractory multiple myeloma, Saint-Antoine Hospital, Sanofi, Sanofi Advances Multiple Myeloma Care in Europe with First Anticancer Therapy Administered via On-Body Injector, Sanofi Secures EU Approval for Sarclisa Subcutaneous as First Anticancer Therapy Delivered Through an On-Body Injector, Sarclisa, Sarclisa IV, Sarclisa subcutaneous, Sarclisa Subcutaneous Approved in the EU as Sanofi Expands Flexible Treatment Options for Multiple Myeloma Patients, Sorbonne University, subcutaneous administration
(IN BRIEF) SCHOTT Pharma has launched the industry’s first 5.5 ml prefillable staked-needle glass syringe, expanding its syriQ BioPure® platform to support biologic therapies designed for home administration. The syringe integrates seamlessly with Ypsomed’s YpsoMate® 5.5 ml autoinjector and Datwyler’s … Read the full press release
Posted in Business, Germany, Healthcare, Industrial, News, Pharma & Biotech, Science, Technology
Tagged Andreas Reisse, autoinjector, biologic therapies, biopharmaceuticals, chronic disease treatment, CPHI Frankfurt, Datwyler, drug delivery, glass syringe, Healthcare Innovation, homecare, large-volume injector, medical technology, patient care, pharmaceutical innovation, SCHOTT Pharma, SCHOTT Pharma and Ypsomed drive innovation in large-volume injectable drug delivery with new 5.5 ml syringe, SCHOTT Pharma unveils 5.5 ml BioPure glass syringe to advance home-based biologic treatments, Subcutaneous Injection, syriQ BioPure, tungsten-free syringe, Ulrike Bauer, YpsoMate, Ypsomed
(IN BRIEF) Evotec, Yonsei University, and Zymedi have been awarded a US$ 4.5 million grant from the Korea Institute of Advanced Technology (KIAT) to develop first-in-class biologic therapies for lung diseases, specifically asthma and idiopathic pulmonary fibrosis (IPF). The project … Read the full press release
Posted in Artificial Intelligence (AI), Business, Education, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged anti-fibrotic antibodies, anti-inflammatory antibodies, antibody development, asthma, biologic therapies, disease-causing enzymes, Evotec, fibrosis, idiopathic pulmonary fibrosis, IPF, KIAT, Korea Institute of Advanced Technology, lung diseases, novel mechanism-of-action, novel therapies, partnership, preclinical R&D, Sunghoon Kim, therapeutic antibodies, Thomas Hanke, tRNA synthetases, unmet medical needs, US$ 4.5 million grant, Yonsei University, Zymedi
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?